DOSAGE FORM FOR INTRAVENOUS APPLICATION SHOULD NOT BE INTRODUCED INSIDE.
The recommendations for the dosage of Tienam® indicated the amount of imipenem to be administered.
The calculation of the total daily dose of Tienam® should be based on the severity of the infection and be divided into several applications at equal doses, taking into account the sensitivity of one or more pathogenic microorganisms, renal function and body weight.
Dosage regimen for adult patients with normal renal function
The dosages given in Table 1 are calculated for patients with normal renal function (creatinine clearance greater than 70 ml / min / 1.73 m2) and body weight ≥ 70 kg. In patients with creatinine clearance ≤ 70 ml / mii / 1.73 m2 (see Table 2) and / or a body weight of less than 70 kg (see Table 3), a reduction in the dose of the drug is necessary. It is especially important to reduce the dose depending on body weight in those patients whose weight is well below 70 kg and / or there is moderate or severe renal failure.
The average therapeutic daily dose is 1-2 g imipenem, divided into 3-4 applications (see Table 1). For treatment of moderate infections, the drug can also be applied at a dose of 1 g twice daily.
In the case of infections caused by less sensitive microorganisms, the daily dose of the drug for intravenous infusions can be increased to a maximum of 4 g (imipenem) per day or 50 mg / kg per day, whichever dose is lower. Each dose of Tienam® for intravenous infusion, less than or equal to 500 mg, should be administered intravenously for 20-30 minutes. Each dose of more than 500 mg should be administered intravenously for 40-60 minutes. Patients who experience nausea during infusion should slow the rate of injection.
Table 1. Dosing regimen of Tienam® for intravenous infusion to adult patients with normal renal function and body weight ≥70 kg*
Severity of infection | Dose imipenem, mg | Break between infusions | Total daily dose |
easy | 250 mg | 6 hours | 1.0 g |
mean | 500 mg | 8 ocloc'k | 1.5 g |
1000 mg | 12 hours | 2.0 g |
Heavy (sensitive pathogens) | 500 mg | 6 hours | 2.0 g |
heavy and / or threatening to life, caused by less sensitive microorganisms (primarily some strains of P. aeruginosa) | 1000 mg | 8 ocloc'k | 3.0 g |
1000 mg | 6 hours | 4.0 g |
*In patients with a body weight of less than 70 kg, a further proportional reduction in the dose to be administered is necessary.
Due to the high antimicrobial activity of Tienam®, it is recommended that its total daily dose not exceed 50 mg / kg or 4 g (imipenem) / day, whichever dose is lower. Although patients with cystic fibrosis with normal renal function were treated with Tienam® at a dose of up to 90 mg / kg per day, divided into several applications, the total dose did not exceed 4 g (imipenem) per day. The drug Tienam ® was successfully used in monotherapy in cancer patients with weakened immunity in the case of confirmed or suspected infections, for example, sepsis.
Dosing schedule for adult patients with impaired renal function
To correct the dose of the drug in the treatment of adult patients with impaired renal function, it is necessary:
- Based on the characteristics of the infection, choose from Table 1 the total daily dose of the drug;
- from Table 2, select the appropriate reduced dose of the drug, based on the daily dose (Table 1) and the creatinine clearance of the patient (to calculate the infusion time,section "Dosage regimen for adult patients with normal renal function");
- from Table 3, choose in the left column the body weight nearest to the patient's body weight (kg).
Table 2. Dosing regimen of Tienam® for intravenous infusions for adult patients with impaired renal function and body weight≥70 kg*
Total daily dose | Clearance creatinine (ml / min / 1.73 m2) |
from Table 1 | 41-70 | 21-40 | 6-20 |
1.0 g per day | 250 mg every 8 hours | 250 mg in 12 hours | 250 mg in 12 hours |
1.5 g per day | 250 mg in 6 hours | 250 mg every 8 hours | 250 mg in 12 hours |
2.0 g per day | 500 mg in 8 hours | 250 mg in 6 hours | 250 mg in 12 hours |
3.0 g per day | 500 mg in 6 hours | 500 mg in 8 hours | 500 mg in 12 hours |
4.0 grams per day | 750 mg in 8 hours | 500 mg in 6 hours | 500 mg in 12 hours |
* Patients with a body weight of less than 70 kg need a further proportional reduction in doses administered.
Table 3. Dosing regimen of Tienam® preparation for the duration of intravenous infusion to adult patients with impaired renal function and / or body weight less than 70 kg
The maximum daily dose of 1.0 g
Body weight (kg) | Creatinine clearance (ml / min / 1.73 m2) |
≥71 | 41-70 | 21-40 | 6-20 |
≥70 | 250 mg each in 6 hours | 250 mg each after 8 hours | 250 mg each in 12 hours | 250 mg each in 12 hours |
60 | 250 mg each after 8 hours | 125 mg in 6 hours | 250 mg each in 12 hours | 125 mg in 12 hours |
50 | 125 mg in 6 hours | 125 mg in 6 hours | 125 mg after 8 hours | 125 mg in 12 hours |
40 | 125 mg in 6 hours | 125 mg after 8 hours | 125 mg in 12 hours | 125 mg in 12 hours |
30 | 125 mg after 8 hours | 125 mg after 8 hours | 125 mg in 12 hours | 125 mg in 12 hours |
The maximum daily dose of 1.5 g
Weight | Creatinine clearance (ml / min / 1.73 m2) |
body weight (kg) | ≥71 | 41-70 | 21-40 | 6-20 |
≥70 | 500 mg each after 8 hours | 250 mg each in 6 hours | 250 mg each after 8 hours | 250 mg each in 12 hours |
60 | 250 mg each in 6 hours | 250 mg each after 8 hours | 250 mg each after 8 hours | 250 mg each in 12 hours |
50 | 250 mg each in 6 hours | 250 mg each after 8 hours | 250 mg each in 12 hours | 250 mg each in 12 hours |
40 | 250 mg each after 8 hours | 125 mg in 6 hours | 125 mg after 8 hours | 125 mg in 12 hours |
30 | 125 mg in 6 hours | 125 mg after 8 hours | 125 mg after 8 hours | 125 mg in 12 hours |
The maximum daily dose of 2.0 g
Weight Tate (kg) | Creatinine clearance (ml / min / 1,73 m2) |
≥71 | 41-70 | 21-40 | 6-20 |
≥70 | 500 mg each in 6 hours | 500 mg each after 8 hours | 250 mg each in 6 hours | 250 mg each in 12 hours |
60 | 500 mg each after 8 hours | 250 mg each in 6 hours | 250 mg each after 8 hours | 250 mg each in 12 hours |
50 | 250 mg each in 6 hours | 250 mg each in 6 hours | 250 mg each after 8 hours | 250 mg each in 12 hours |
40 | 250 mg each in 6 hours | 250 mg each after 8 hours | 250 mg each in 12 hours | 250 mg each in 12 hours |
30 | 250 mg each after 8 hours | 125 mg in 6 hours | 125 mg after 8 hours | 125 mg in 12 hours |
The maximum daily dose of 3.0 g
Weight Tate (kg) | Creatinine clearance (ml / min / 1.73 m2) |
≥71 | 41-70 | 21-40 | 6-20 |
≥70 | 1000 mg after 8 hours | 500 mg each in 6 hours | 500 mg each after 8 hours | 500 mg each in 12 hours |
50 | 750 mg after 8 hours | 500 mg each after 8 hours | 500 mg each after 8 hours | 500 mg each in 12 hours |
50 | 500 mg each in 6 hours | 500 mg each after 8 hours | 250 mg each in 6 hours | 250 mg each in 12 hours |
40 | 500 mg each after 8 hours | 250 mg each in 6 hours | 250 mg each after 8 hours | 250 mg each in 12 hours |
30 | 250 mg each in 6 hours | 250 mg each after 8 hours | 250 mg each after 8 hours | 250 mg each in 12 hours |
The maximum daily dose of 4.0 g
Body weight (kg) | Creatinine clearance (ml / min / 1.73 m2) |
≥71 | 41-70 | 21-40 | 6-20 |
≥70 | 1000 mg in 6 hours | 750 mg after 8 hours | 500 mg each in 6 hours | 500 mg each in 12 hours |
60 | 1000 mg after 8 hours | 750 mg after 8 hours | 500 mg each after 8 hours | 500 mg each in 12 hours |
50 | 750 mg after 8 hours | 500 mg each in 6 hours | 500 mg each after 8 hours | 500 mg each in 12 hours |
40 | 500 mg each in 6 hours | 500 mg each after 8 hours | 250 mg each in 6 hours | 250 mg each in 12 hours |
50 | 500 mg each after 8 hours | 250 mg each in 6 hours | 250 mg each after 8 hours | 250 mg each in 12 hours |
When a dose of 500 mg is administered to patients with a creatinine clearance of 6-20 ml / min / 1.73 m2 may increase the risk of seizures.
The drug Tienam® should not be administered intravenously to patients with creatinine clearance less than 5 ml / min / 1.73 m2 With the exception of cases where hemodialysis will be performed no later than 48 hours after the infusion of Tienam®.
Hemodialysis
When treating patients with creatinine clearance less than 5 ml / min / 1.73 m2, on hemodialysis, recommendations should be applied but the dosage regimen of Tienam® for patients with creatinine clearance 6-20 ml / min / 1.73 m2 (see the section "Treatment: Dosage Scheme for Adult Patients with Impaired Renal Function").
Both imipenem and cilastatin are excreted during hemodialysis from the circulatory system. In this regard, the drug Tienam® for intravenous infusions should be administered to patients after hemodialysis and then at 12-hour intervals from the end of the procedure. Patients on hemodialysis, especially if they have central nervous system diseases, should be carefully monitored; the administration of Tienam® to patients undergoing hemodialysis is recommended only when the benefits of treatment exceed the potential risk of seizures (see Table 1).see "With caution").
At present, there is insufficient data to recommend the drug Tienam® for intravenous administration to patients on peritoneal dialysis.
The state of the kidney in elderly patients can not be fully determined only on the basis of measuring the level of residual blood nitrogen or creatinine. To determine the dosage of such patients, it is recommended to determine the clearance of creatinine.
Elderly patients
For elderly patients with normal renal function, dose adjustment is not required.
Impaired liver function
For patients with impaired liver function, dose adjustment is not required.
Prevention: dosing regimen for adult patients
To prevent postoperative infections in adults, the Tienam® preparation for intravenous infusions should be administered at a dose of 1 g for anesthesia and then 1 g after 3 hoursa. In the case of surgical intervention with a high degree of risk (for example, in operations on the thick and rectum), two additional doses of 500 mg should be administered at 8 and 16 hours after the initial anesthesia.
Dosage regimen for children from 3 months of age
The following dosing regimen is recommended for children:
- Children with a body weight of ≥40 kg should receive the same doses as adult patients.
- Children older than 3 months with a body weight of less than 40 kg should receive the drug at a dose of 15 mg / kg at 6-hour intervals. The maximum daily dose should not exceed 2 g.
The drug Tienam® is not recommended for the treatment of meningitis. If suspected of having meningitis, appropriate antibiotics should be prescribed.
Preparation of a solution for intravenous infusion
The drug Tienam® for intravenous infusion should not be mixed or added to other antibiotics.
The drug form of Tienam® for intravenous infusions is chemically incompatible with lactic acid (lactate) and should not be prepared on the basis of solvents containing lactate. However, intravenously, the Tienam® preparation can be administered via the same infusion system as the lactate-containing solution.
A solution of the preparation Tienam® for intravenous infusions is prepared in accordance with the following Table 4. The final infusion solution must be shaken until a clear solution is obtained.The color of the solutions of the preparation Tienam® varies from colorless to yellow (a change in color within these limits does not affect the activity of the drug).
Table 4. Preparation of Tienam® Solution for Intravenous Infusions
The dose of Tienam® for intravenous infusions (mg imipenem) | Volume of solvent added (ml) | The average concept of the infusion solution of Tienam® (mg / ml imipenem) |
500 | 100 | 5 |
For a bottle of 20 ml
The vial Tienam® previously necessary to add 10 ml of the solvent from the list presented in Table 5. The obtained primary slurry must be thoroughly shake and add an infusion bottle containing 90 ml of solvent infusion.
PRIMARY SUSPENSION CAN NOT BE USED FOR INTRODUCTION.
For the complete transfer of the drug, the procedure must be repeated by adding 10 ml of the previously obtained solution from the infusion bottle to the vial of powder residues. The resulting suspension should be thoroughly shaken and added to an infusion bottle containing 90 ml of an infusion solvent.
The total volume of the solvent is 100 ml.
The final infusion solution must be shaken until a clear solution is obtained.
Table 5 shows the timing of the use of the infusion solution of Tienam®, prepared from a number of infusion solvents and stored at room temperature or in a refrigerator.
Table 5.
Solvent | The period of stability n | rhyarate |
| Room temperature (25 ° C) | Refrigerator (4 ° C) |
0.9% solution of sodium chloride | 4 hours | 24 hours |
5% dextrose solution | 4 hours | 24 hours |
10% dextrose solution | 4 hours | 24 hours |
5% dextrose solution and 0.9% sodium chloride solution | 4 hours | 24 hours |
5% dextrose solution and 0.45% sodium chloride solution | 4 hours | 24 hours |
5% dextrose solution and 0.225% sodium chloride solution | 4 hours | 24 hours |
5% dextrose solution and 0.15% potassium chloride solution | 4 hours | 24 hours |
5% and 10% mannitol solution | 4 hours | 24 hours |